Wyeth mulls global sales force restructuring

Share this article:
Wyeth said the restructuring of its U.S. sales force was only a start and that it is considering making similar changes globally.
"Obviously it is a first step. We're also looking internationally. Our European affiliates have started to look at how to optimize the sales force," said Bernard Poussot, head of Wyeth's pharmaceutical operations said in a Financial Times report.
Last month, Wyeth said it would use inside, part-time sales representatives in the U.S. to complement its full-time sales force, which is being reduced by about 25 percent to 30 percent.
Adding the part-timers will result in a net sales force reduction of about 15 percent, Poussot said.
Wyeth has deployed part-timers in its consumer division for the past few years.
As reported in MM&M, the drug maker began piloting them in its pharmaceuticals division in July and said it will fully implement them by year's end (MM&M, July 2005).
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...